Pictet Asset Management (Switzerland)’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $37.2M | Sell |
5,286,536
-331,836
| -6% | -$2.34M | 0.04% | 345 |
|
|
2023
Q1 | $46.9M | Buy |
5,618,372
+333,024
| +6% | +$2.78M | 0.06% | 291 |
|
|
2022
Q4 | $60.7M | Buy |
5,285,348
+471,576
| +10% | +$5.41M | 0.09% | 242 |
|
|
2022
Q3 | $60.7M | Sell |
4,813,772
-1,233,189
| -20% | -$15.5M | 0.09% | 243 |
|
|
2022
Q2 | $64M | Buy |
6,046,961
+940,058
| +18% | +$9.95M | 0.09% | 245 |
|
|
2022
Q1 | $83M | Buy |
5,106,903
+51,639
| +1% | +$840K | 0.09% | 242 |
|
|
2021
Q4 | $70M | Buy |
5,055,264
+5,043,299
| +42,150% | +$69.8M | 0.07% | 285 |
|
|
2021
Q3 | $172K | Buy |
+11,965
| New | +$172K | ﹤0.01% | 1631 |
|